Healthcare

The company delivered a positive operating profit of $0.4 million for FY26, alongside continuedInvestmentin its product portfolio, with $3.7 million capitalised during the year. Liquidity stood at $5.5 million as at 30 June 2026, comprising $2.5 million in cash and a $3.0 million undrawn …

The increase in the AN-ACC price reflects the Australian Government's annual pricing determination, based on advice from the Independent Health and Aged Care Pricing Authority (IHACPA). The Government has also confirmed that current care minute requirements and AN-ACC fixed and variable funding categories will …

Genetic Signatures Limited (ASX:GSS) has become the subject of aShareholderand governance development after raising questions over the shareholding position of BCAL Diagnostics Ltd and receiving a formal request for a shareholder meeting to consider changes to its board.

Turkey was added to the ITL distribution territory following CE Mark approval and the expansion of the agreement in September 2025. The first commercial sale in Turkey has now been completed, comprising 100 Felix cartridges and two consoles, providing an installed platform from which …

Imricor Medical Systems (ASX:IMR) has received notification from the U.S. Food and Drug Administration that its manufacturing module under the company’s Premarket Approval submission has been evaluated, accepted and formally closed.

For FY26, Aroa reportedRevenueof around NZ$104 million, up 23%, and a second consecutive year of positive EBITDA, with normalised EBITDA tripling, exceeding its FY26 guidance. The company set ambitious FY27 targets and emphasised its United States growth strategy, including the Symphony and Enivo product …

In its first half of FY26, nib (ASX:NHF) reportedRevenueof A$1.9 billion, up 7.7%, withUnderwritingoperating profit surging 22% to A$129.1 million and net profit after tax of A$82.9 million, and it declared anInterim Dividendof 13.0 cents.